Analysis of variation in L-365,260 competition curves in radioligand binding assays

被引:30
作者
Harper, EA
Roberts, SP
Shankley, NP
Black, JW
机构
[1] James Black Foundation, Dulwich, London SE24 9JE
关键词
cholecystokinin; gastrin; mouse cortex; rat cortex; guinea-pig gastric glands; L-365,260; I-125]-BH-CCK8S;
D O I
10.1111/j.1476-5381.1996.tb15597.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 For several years, we have used the cholecystokinin (CCK)(B)/gastrin receptor selective antagonist, L-365,260, as a reference compound in a variety of studies in CCKB/gastrin receptor radioligand binding assays. Here, we have analysed the competition curve data sets obtained between L-365,260 and [I-125]-BH-CCK8S in guinea-pig gastric gland and mouse and rat cerebral cortex preparations. 2 Competition curves obtained for L-365,260 in the mouse cortex assay were not different from rectangular hyperbolae (slope = 1.01 +/- 0.02) implying the presence of a single population of binding sites (pK(I) = 8.41 +/- 0.01; data from 47 experiments, slope constrained to unity). However, in the rat cortex and guinea-pig gastric gland assays, the mean slope of the competition curves was significantly less than one and the mean apparent pK(I) significantly lower than that obtained in the mouse cortex (slope = 0.85 +/- 0.03, 0.90 +/- 0.03; apparent pK(I) = 7.98 +/- 0.05, 8.07 +/- 0.05; 48 and 45 experiments, in rat and guinea-pig, respectively). The distribution of the individual pK(I) and slope estimates of the competition curves in these two assays was consistent with expectations for the variable expression (in terms of absolute number and proportion) of two binding sites. The two sites were characterized by pK(I) values for L-365,260 of 8.50 +/- 0.04 and 8.48 +/- 0.04 for the high affinity site and 7.32 +/- 0.04 and 7.22 +/- 0.06 for the low affinity site in guinea-pig and rat, respectively. 3 The affinity estimates for L-365,260, although obtained on different tissues, are consistent with data obtained from the analysis of L-365,260 antagonism of pentagastrin-stimulated responses in mouse and rat stomach (acid secretion) and guinea-pig gastric muscle (isotonic contraction) assays. To this extent, these data suggest the existence of two CCKB/gastrin receptor subtypes.
引用
收藏
页码:1717 / 1726
页数:10
相关论文
共 52 条
[1]   A SINGLE AMINO-ACID OF THE CHOLECYSTOKININ-B GASTRIN RECEPTOR DETERMINES SPECIFICITY FOR NONPEPTIDE ANTAGONISTS [J].
BEINBORN, M ;
LEE, YM ;
MCBRIDE, EW ;
QUINN, SM ;
KOPIN, AS .
NATURE, 1993, 362 (6418) :348-350
[2]   PHARMACOLOGICAL PROPERTIES OF UREIDO-ACETAMIDES, NEW POTENT AND SELECTIVE NONPEPTIDE CCK(B)/GASTRIN RECEPTOR ANTAGONISTS [J].
BERTRAND, P ;
BOHME, GA ;
DURIEUX, C ;
GUYON, C ;
CAPET, M ;
JEANTAUD, B ;
BOUDEAU, P ;
DUCOS, B ;
PENDLEY, CE ;
MARTIN, GE ;
FLOCH, A ;
DOBLE, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 262 (03) :233-245
[3]   ENDOTHELIN SARAFOTOXIN RECEPTOR HETEROGENEITY - EVIDENCE FOR DIFFERENT GLYCOSYLATION IN RECEPTORS FROM DIFFERENT TISSUES [J].
BOUSSOMITTLER, D ;
GALRON, R ;
SOKOLOVSKY, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 178 (03) :921-926
[4]   CHARACTERIZATION OF [H-3] PENTAGASTRIN BINDING IN GUINEA-PIG GASTRIC GLANDS - AN ALTERNATIVE CONVENIENT LIGAND FOR RECEPTOR-BINDING ASSAY [J].
CHANG, RSL ;
LOTTI, VJ ;
KEEGAN, ME ;
KUNKEL, KA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 134 (02) :895-899
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   A STUDY OF THE CEREBRAL-CORTEX CHOLECYSTOKININ RECEPTOR USING 2 RADIOLABELED PROBES - EVIDENCE FOR A COMMON CCK-8 AND CCK-4 CHOLECYSTOKININ RECEPTOR-BINDING SITE [J].
CLARK, CR ;
DAUM, P ;
HUGHES, J .
JOURNAL OF NEUROCHEMISTRY, 1986, 46 (04) :1094-1101
[7]   CHARACTERIZATION OF TYPE-A AND TYPE-B CCK RECEPTOR-BINDING SITES IN RAT VAGUS NERVE [J].
CORP, ES ;
MCQUADE, J ;
MORAN, TH ;
SMITH, GP .
BRAIN RESEARCH, 1993, 623 (01) :161-166
[8]   MOLECULAR AND PHARMACOLOGICAL CHARACTERIZATION OF THE HUMAN CCKB RECEPTOR [J].
DENYER, J ;
GRAY, J ;
WONG, M ;
STOLZ, M ;
TATE, S .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 268 (01) :29-41
[9]  
DIXON WJ, 1992, BMDP STATISTICAL SOF
[10]  
DURIEUX C, 1992, MOL PHARMACOL, V42, P1089